NewAmsterdam Pharma’s Promising Developments and EU Approval Prospects Drive Buy Rating

Analyst Serge Belanger from Needham maintained a Buy rating on NewAmsterdam Pharma Company and increased the price target to $46.00 from $40.00.

Serge Belanger has given his Buy rating due to a combination of factors including the promising developments surrounding NewAmsterdam Pharma’s obicetrapib (obi). The acceptance of the Marketing Authorization Application (MAA) for obi in the European Union signifies a potential approval by the second half of 2026, which could lead to significant royalty income for NAMS, ranging from low-double digits to mid-20s.
Additionally, investor attention is centered on the PREVAIL cardiovascular outcomes trial, which aims to validate the one-year major adverse cardiovascular event (MACE) reduction observed in the earlier BROADWAY trial. This trial is event-driven, with results anticipated between the second half of 2026 and the first half of 2027. The potential of obi as a lipid-lowering therapy and the expected financial benefits from EU royalties underpin the Buy rating, with a price target adjustment to $46.

According to TipRanks, Belanger is a 4-star analyst with an average return of 8.4% and a 47.60% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Cormedix, Amphastar Pharmaceuticals, and Viridian Therapeutics.

In another report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $52.00 price target.